Bio-Rad Launches Its Western Blot Learning Center, an Online Multi-media Library of Resources on Immunoblotting
HERCULES, Calif.–January 22, 2021–Bio-Rad Laboratories, Inc., (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the Bio-Rad Western Blotting Learning Center, an online library that provides comprehensive resources, information, and guidance to help researchers improve their experimental western blotting (or immunoblotting) approaches to obtain high-quality data.
The Bio-Rad Western Blot Learning Center, available on bio-rad.com, was created to provide researchers an online platform to learn about western blotting, leveraging Bio-Rad’s experience and expertise in western blotting as well as protein electrophoresis that spans decades. The center offers comprehensive information on the science of western blotting, best practices, tips and techniques, as well as guidance on how to troubleshoot experiments.
“We’re delighted to share our experiences with researchers to help them optimize their experiments and achieve more reliable results,” said Ben Wang, Bio-Rad Global Product Manager of Electrophoresis and Western Blotting Products, Life Science Group. “The Bio-Rad Western Blot Learning Center extends our support to researchers, offering insights and techniques on blotting from our experts,” he added.
Electrophoresis and western blotting are standard research methods used to characterize proteins. Bio-Rad offers a complete workflow solution for protein detection and quantitation featuring proprietary stain-free imaging technology, primary and secondary antibodies, as well as fluorescent and chemiluminescent imaging systems.
Please visit bio-rad.com/LearnWestern to learn more information about the Bio-Rad Western Blot Learning Center.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@